<DOC>
	<DOCNO>NCT01371604</DOCNO>
	<brief_summary>The purpose study assess safety antiviral activity IDX184 combination pegylated interferon ribavirin treatment-na√Øve subject genotype 1 chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Antiviral Activity IDX184 Combination With Pegylated Interferon Ribavirin 12 Weeks ( MK-2355-005 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Males female document genotype 1 , chronic hepatitis C infection . Must agree use doublebarrier method birth control least 6 month last dose study drug . Has receive prior antiviral treatment HCV . Written inform consent participant . Pregnant breastfeeding . Coinfected hepatitis B virus ( HBV ; hepatitis B surface antigen [ HBsAg ] positive ) and/or human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>treatment-naive</keyword>
</DOC>